Shijiazhuang Yiling Pharmaceutical (002603) Q4 2025 earnings summary

Executive summary

• Achieved revenue of ¥7.83 billion in 2025, up 20.24% year-over-year; net profit attributable to shareholders was ¥1.29 billion, a 277.56% increase year-over-year.

• Operating cash flow reached ¥1.78 billion, up 190.75% year-over-year.

• Major product lines include patented Chinese medicines, chemical pharmaceuticals, and health products, with strong performance in cardiovascular and respiratory segments.

• Maintained high R&D investment at ¥788 million, representing 10.07% of revenue.

• Proposed total cash dividend payout of ¥1.34 billion, exceeding net profit for the year.

Financial highlights

• Revenue: ¥7.83 billion (+20.24% YoY); net profit: ¥1.29 billion (+277.56% YoY).

• Gross margin for main products: cardiovascular 68.60%, respiratory 75.16%.

• Operating cash flow: ¥1.78 billion (+190.75% YoY).

• Basic and diluted EPS: ¥0.77 (vs. -¥0.43 last year).

• R&D expense: ¥788 million (10.07% of revenue).

Outlook and guidance

• Will continue to strengthen core product promotion, expand into new therapeutic areas, and accelerate new drug launches.

• Plans to optimize cost structure, enhance digital marketing, and maintain high R&D investment.

• Expects continued growth in cardiovascular, respiratory, and health product segments.